Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

A Clinical Study on Acuris™ - Conometric Concept for Single Tooth Restoration

NCT04063878 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2019-07-30
Last updated
2026-09-18

Condition(s) studied

Jaw, Edentulous, Partially

Investigational drug(s) / intervention(s)

Conometric Abutment and Conometric Final Cap

Conometric Abutment and Conometric Final Cap: Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.

Study summary

The purpose of this study is to evaluate the outcome of prosthetic survival of the Acuris conometric concept 1 year after permanent restoration, since this is a new mode of retention using friction for seating the crown of single tooth restorations without using cement or screws.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Subject aged between 18-75 years 2. Subject signed and dated the informed consent form 3. In need of an implant replacing a missing tooth in position 17 to 27 or 37 to 47, and each subject can only receive one study implant. 4. Neighbouring tooth to the planned implant must have * a natural root or an implant supported restoration mesially * a natural root or an implant supported restoration distally Exemption: If the planned implant is in the second molar position, an edentulous space is accepted distally. 5. Presence of natural tooth, partial prosthesis and/or implant supported restoration in the opposite jaw in contact with the planned crown 6. Deemed by the investigator as likely to present an initially stable implant situation Exclusion Criteria: 1. Unlikely to be able to comply with study procedures, according to Investigators judgement 2. Subject is not willing to participate in the study or not able to understand the content of the study 3. Involvement in the planning and conduct of the study 4. Severe non-compliance to CIP as judged by the Investigator and/or Dentsply Sirona Implants. 5. Unable or unwilling to return for follow-up visits for a period of five years 6. Simultaneous participation in another clinical study, or former participation in a clinical study during the last 6 months that may interfere with the present study 7. Previous enrolment in the present study 8. Uncontrolled pathological process in the oral cavity 9. Known or suspected current malignancy 10. History of radiation therapy in the head and neck region within 12 months prior to surgery 11. Systemic or local disease or condition that could compromise post-operative healing and/or osseointegration 12. Uncontrolled diabetes mellitus 13. Corticosteroids, iv bisphosphonates or any other medication that could influence post-operative healing and/or osseointegration 14. Current need for major bone grafting and/or augmentation in the planned implant area (minor grafting and soft tissue grafting are allowed) 15. Smoking more than 10 cigarettes per day, present alcohol or drug abuse 16. Known pregnancy at implant installation (Only applicable for sites in United States and Canada)

Primary outcome measure(s)

  • Prosthetic Survival — 1 year after permanent restoration
    Evaluation of presence of original permanent restoration, remained retention between abutment and final cap, and occurrence of fracture/loss of abutment. Prosthetic survival will be categorized as No/Yes. It will be categorized as "Yes" if all of the following criteria are fulfilled: * Permanent restoration is remaining in situ. * No loss of conometric retention between abutment and final cap. * No fracture of abutment. * No loss of abutment.

Trial sites (9)

FacilityCityRegionStatus
University of Illinois College of Dentistry Chicago Illinois
Implant & Prosthodontic Associates Oklahoma City Oklahoma
Cholakis Dental Group Winnipeg Canada
Praxis Prof. Dr. Dhom & Kollegen MVZ GmbH Ludwigshafen Germany
Studio Toia Busto Arsizio Italy
Clínica Dental Broseta Cheste Spain
Clinica Dental Antuña de Alaiz SL Oviedo Spain
Ten Dental London United Kingdom
The Implant Experts LTD Maidstone United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04063878 on ClinicalTrials.gov ↗ ← All trials in Spain